Galunisertib co-administered with durvalumab was tolerable, but with limited clinical activity which required the selection of predictive biomarkers for TGF-β inhibition in pancreatic cancer patients (NCT02734160) [365]. The gene discussed is TGFB1; the disease is pancreatic neoplasm.